Teva Pharma (TEVA) Tops Q3 EPS by 11c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Teva Reports Third Quarter 2018 Financial Results
November 1, 2018 7:00 AM EDTRevenues of $4.5 billion Free cash flow of $704 million GAAP diluted loss per share of $0.27 Non-GAAP diluted EPS of $0.68 Spend base reduction of $1.8 billion in the first nine months of 2018; on-track to achieve $3.0 billion by the end of 2019 AJOVY (fremanezumab) was approved by the FDA in September 2018 and immediately launched Raising 2018 full year guidance: Non-GAAP EPS guidance raised to $2.80-2.95 from $2.55-2.80 Free cash flow guidance raised to $3.6-3.8 billion from... More
